Gastroenterology & GI Surgery

Welcome to the Mayo Clinic Gastroenterology & GI Surgery Page! With one of the largest group of digestive disease specialists in the world, Mayo Clinic has been recognized as the nation's best Gastroenterology & GI Surgery hospital by U.S. News & World Report.
Follow the page to read shared experiences, learn about clinical trials and up-to-date research, and find resources for all your gastroenterology needs. Our goal is to connect you to others, and become informed decision makers; so post a comment, share your story, own your health.

PUBLIC PAGE
Thu, Dec 18, 2014 9:21am

Vedolizumab Is Better for Ulcerative Colitis Than Crohn's Disease

By Kanaaz Pereira, Connect Moderator, @kanaazpereira

In December 2013, two Food and Drug Administration (FDA) advisory committees voted in favor of recommending vedolizumab for treatment of both types of inflammatory bowel disease. A theoretical concern about vedolizumab is the risk of progressive multifocal leukoencephalopathy (PML), a potentially fatal brain infection associated with vedolizumab's parent molecule, natalizumab (Tysabri), which is approved for use in both multiple sclerosis and CD. Edward V. Loftus Jr., M.D., a gastroenterologist at Mayo Clinic in Minnesota, points out that natalizumab affects adhesion molecules at the level of the blood-brain barrier system as well as in the gut. "The goal has always been to develop more gut-specific targets," he says.

Read more about vedolizumab in the Digestive Diseases update.

To learn more about IBD, visit mayoclinic.org/ibd.

Please login or register to post a reply.

Invite Others

Send an email to invite people you know to join the Gastroenterology & GI Surgery page.

We'll include this text in the user's invitation.